* Leap Therapeutics Inc LPTX.OQ reported a quarterly
adjusted
loss of 44 cents per share for the quarter , higher than the
same quarter last year, when the company reported EPS of -51
cents. The mean expectation of four analysts for the quarter
was for a loss of 48 cents per share. Wall Street expected
results to range from -53 cents to -37 cents per share.
* Reported revenue was zero; analysts expected zero.
* Leap Therapeutics Inc's reported EPS for the quarter was a
loss
of 44 cents.
* The company reported a quarterly loss of $18.18 million.
* Leap Therapeutics Inc shares had risen by 26.5% this
quarter and
lost 21.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Leap Therapeutics
Inc is 12.00
This summary was machine generated from LSEG data November 13 at
02:16 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.48 -0.44 Beat
Jun. 30 2024 -0.43 -0.52 Missed
Mar. 31 2024 -0.58 -0.51 Beat
Dec. 31 2023 -0.55 -0.46 Beat